Recursion Pharmaceuticals, Inc. (RXRX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Join SI Premium – FREE
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q3 EPS of ($0.36), $0.01 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $16.95 million.
For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
- IndeRes Upgrades Nokia OYJ (NOKIA:FH) (NOK) to Reduce (3)
- Bank of India (BOI:IN) PT Lowered to INR150 at ICICI Securities
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
